Other COVID-19 Vaccine Related Codes
On This Page
COVID-19 Vaccine Codes
Preview Posting of COVID-19 Vaccine Codes and Crosswalk for Currently Authorized Vaccines and Anticipation of Potential Vaccine Availability under Emergency Use Authorization (EUA)
Note: Codes will become effective only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA)
The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization.
The following downloadable table provides a summary of the currently authorized vaccine codes and a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines.
To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance.
The codes for these vaccines are also included in the vaccine code set files unless otherwise noted in the table. Additional code details and fields values are included in the vaccine code sets.
American Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site. The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets. You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:
https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes
Previous COVID-19 Vaccine Codes Only. The following U.S. COVID-19 vaccine codes table does not include the Fall 2023 COVID-19 vaccine codes and crosswalks. Download the Fall 2023 COVID-19 Codes: Excel version can be found here.
Download the Previous Preview Table for US vaccine administration only: Excel Version
COVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA). Codes will become effective for US vaccine administrations only upon EUA issuance and/or BLA approval of COVID-19 vaccine(s) by the FDA. All CVX codes are associated to the new Vaccine Group “COVID-19.” CPT codes shown are product codes. CPT administrative codes for doses are available on the AMA website. CPT product codes are added as the AMA approves and makes them available.
| Manufacturer | FDA Authorization (BLA, EUA, Pre-EUA) |
Sale Proprietary Name | Product Description | Unit of Sale NDC10 (UOS) | UoS Package | Unit of Use NDC10 (UOU) | UoU Presentation | CVX Code | CVX Long Description | CVX Short Description | MVX Code | CPT Product Code | CPT Description |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Products, LP | EUA-authorized (18+) | Janssen COVID-19 Vaccine
(BLUE CAP) |
5×10^10 viral particles/0.5 mL for adult 18+ | 59676-580-15 | CARTON, 10 MULTI-DOSE VIALS | 59676-580-05 | VIAL, MULTI-DOSE | 212 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | JSN | 91303 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral particles/0.5 mL dosage, for intramuscular use |
| Moderna US, Inc. | FDA EUA update of 04/18/2023 rescinds use of this monovalent vaccine.
EUA-authorized (ages 12 yrs +) |
Moderna COVID-19 Vaccine
(RED CAP) |
100 mcg/0.5 mL for adult primary series and IC dose 12+ (existing product) | 80777-273-99 | CARTON, 10 MULTI-DOSE VIAL 5 mL EACH | 80777-273-10 | VIAL, 5 mL, MULTI-DOSE VIAL | 207 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | MOD | 91301 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use |
| 80777-273-98 | CARTON, 10 MULTI-DOSE VIAL 7 mL EACH | 80777-273-15 | VIAL, 7 mL, MULTI-DOSE VIAL | ||||||||||
| Moderna US, Inc. | FDA EUA update of 04/18/2023 rescinds use of this monovalent vaccine.
EUA-authorized (ages 18 yrs +) |
Moderna COVID-19 Vaccine
(RED CAP) |
50 mcg/0.25 mL for booster dose adults 18+ (existing product), drawn from same vial as primary series. On 8/31/2022, EUA rescinded for adult monovalent booster. Only bivalent booster should be administered. | 80777-273-99 | CARTON, 10 MULTI-DOSE VIAL 5 mL EACH | 80777-273-10 | VIAL, 5 mL, MULTI-DOSE VIAL | 207 | MOD | 91306 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use | ||
| 80777-273-98 | CARTON, 10 MULTI-DOSE VIAL 7 mL EACH | 80777-273-15 | VIAL, 7 mL, MULTI-DOSE VIAL | ||||||||||
| Moderna US, Inc. | BLA-licensed for ages 18 yrs +
Use of this monovalent product discontinued for US administration consistent with FDA EUA updates of 04/18/2023 regarding EUA monovalent mRNA products. |
SPIKEVAX Moderna COVID-19 Vaccine(RED CAP) |
100 mcg/0.5 mL for adult 18+ (Same formulation and concentration as EUA product) | 80777-100-99 | CARTON, 10 MULTI-DOSE VIAL 5.5 mL EACH | 80777-100-11 | VIAL, 5.5 mL, MULTI-DOSE VIAL | 207 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose | MOD | 91301 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use |
| Moderna US, Inc. | FDA EUA update of 04/18/2023 rescinds use of this monovalent vaccine
EUA-authorized |
Moderna COVID-19 Vaccine Booster
(BLUE CAP) |
New concentration, 50 mcg/0.50 mL for booster dose adults 18+ yrs, also authorized for primary series and IC doses for ages 6 years to <12 years. On 8/31/2022, EUA rescinded adult booster dose from this vial. EUA continued for 6 years to <12 year primary and IC doses. | 80777-275-99 | CARTON, 10 MULTI-DOSE VIAL 2.5 mL EACH | 80777-275-05 | VIAL, 2.5 mL, MULTI-DOSE VIAL | 221 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose | MOD | 91309 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use |
| Moderna US, Inc. | FDA EUA update of 04/18/2023 rescinds use of this monovalent vaccine.
EUA-authorized for ages 6 months to < 6 years |
Moderna COVID-19 Vaccine Pediatric Vaccine(BLUE CAP) |
25 mcg/0.25 mL dose For pediatric primary series and IC doses for ages 6 mo to <6 years | 80777-279-99 | CARTON, 10 MULTI-DOSE VIAL 2.5 mL EACH | 80777-279-05 | VIAL, 2.5 mL, MULTI-DOSE VIAL | 228 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose | COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose | MOD | 91311 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use |
| Moderna US, Inc. | FDA EUA updated 04/18/2023. Authorizes bivalent vaccine dosing for ages 6 mo and older.
Rescinds authorization for monovalent vaccines. |
Moderna COVID-19 Vaccine Bivalent Original and Omicron BA.4 & BA.5 COVID-19 strains(DARK BLUE CAP – Label with Gray Border) |
Ages 12 yrs and older: 50 mcg/0.5 mL adult dose for single-dose and additional doses if appropriate.Ages 6 yrs to < 12 yrs: 25 mcg/0.25 mL dose for single-dose and additional doses if appropriate.Ages 6 mos to < 6 yrs: 25 mcg/0.25 mL dose for Dose 1 and Dose 2 and additional doses if appropriate. |
80777-282-99 | CARTON, 10 MULTI-DOSE VIALS | 80777-282-05 | VIAL, 2.5 mL, MULTI-DOSE | 229 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25mcg/0.25mL dose | COVID-19, mRNA, LNP-S, bivalent, PF, 50 mcg/0.5 mL or 25mcg/0.25mL dose | MOD | 91313 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use |
| 91314 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use | ||||||||||||
| Moderna US, Inc. | FDA EUA updated 04/18/2023. Authorizes dosing for Dose 3 and additional doses for ages 6 mo to < 6 yrs
Rescinds authorization for monovalent vaccines. |
Moderna COVID-19 Vaccine Bivalent, Original and Omicron BA.4 & BA.5 COVID-19 strains for 6m through 5y(DARK PINK CAP – Label with Yellow Box) |
Ages 6 mos to < 6 yrs: 10 mcg/0.2 mL dose for Dose 3 and additional doses after Dose 1 and Dose 2 of 25 mcg/0.25mL, if appropriate |
80777-283-99 | CARTON, 10 MULTI-DOSE VIALS | 80777-283-02 | VIAL, 0.4 mL, MULTI-DOSE | 230 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL | MOD | 91316 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use |
| Pfizer-BioNTech | FDA EUA update 04/18/2023 rescinds use of this monovalent vaccine.EUA-authorized for ages 12 yrs + | Pfizer-BioNTech COVID-19 Vaccine
(PURPLE CAP) (Original product formulation) |
30 mcg/0.3 mL for primary series, IC 3rd dose and boosters. | 59267-1000-2 | CARTON, 195 MULTI-DOSE VIALS | 59267-1000-1 | MULTI-DOSE VIAL | 208 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | PFR | 91300 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use |
| 59267-1000-3 | CARTON, 25 MULTI-DOSE VIALS | ||||||||||||
| Pfizer-BioNTech | FDA EUA update 04/18/2023 rescinds use of this monovalent vaccine.EUA-authorized for ages 12 yrs + | Pfizer-BioNTech COVID-19 Vaccine
(GRAY CAP) (Tris-sucrose formulation) |
30 mcg/0.3 D9mL for primary series, IC 3rd dose and boosters. | 59267-1025-3 | CARTON, 25 MULTI-DOSE VIALS | 59267-1025-1 | VIAL, 2.25 mL, MULTI-DOSE VIAL | 217 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR | 91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| 59267-1025-4 | CARTON, 10 MULTI-DOSE VIALS | ||||||||||||
| Pfizer-BioNTech | BLA-licensed for ages 12 yrs +
This BLA remains in place, but use of this monovalent product will be discontinued for US administration consistent with FDA EUA updates of 04/18/2023 regarding EUA monovalent mRNA products. |
COMIRNATY
(GRAY CAP) |
30 mcg/0.3 mL for adult 12 yrs + (Same as EUA tris sucrose formula) | 0069-2025-10 | CARTON, 10 MULTI-DOSE VIALS | 0069-2025-01 | VIAL, 2 mL, MULTI-DOSE VIAL | 217 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose | PFR | 91305 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| 0069-2025-25 | CARTON, 25 MULTI-DOSE VIALS | ||||||||||||
| Pfizer-BioNTech | FDA EUA update 04/18/2023 rescinds use of this monovalent vaccine.
EUA-authorized for ages 5 yrs to < 12 yrs |
Pfizer-BioNTech COVID-19 Vaccine
(ORANGE CAP) (Tris-sucrose formulation) |
10 mcg/0.2 mL for primary series, IC 3rd dose, booster | 59267-1055-4 | CARTON, 10 MULTI-DOSE VIALS | 59267-1055-1 | VIAL, 2 mL, MULTI-DOSE VIAL | 218 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose | PFR | 91307 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use |
| Pfizer-BioNTech | FDA EUA update 04/18/2023 rescinds use of this monovalent vaccine.EUA-authorized for ages 6 mo to <5 yrs | Pfizer-BioNTech COVID-19 Vaccine
(MAROON CAP) (Tris-sucrose formulation) |
3 mcg/0.2 mL for primary series | 59267-0078-4 | CARTON, 10 MULTI-DOSE VIALS | 59267-0078-1 | VIAL, 2 mL, MULTI-DOSE VIAL | 219 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose | PFR | 91308 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use |
| Pfizer-BioNTech | FDA EUA updated 04/18/2023. Authorizes bivalent single-dose plus additional dose if applicable, rescinds authorization for monovalent vaccines. | Pfizer-BioNTech COVID-19 Vaccine Bivalent 12 years and older(GRAY CAP)(Tris-sucrose formulation) |
30 mcg/0.3 mL dose Original and Omicron BA.4 & BA.5 COVID-19 strains |
59267-0304-2 | CARTON, 10 MULTI-DOSE VIALS | 59267-0304-1 | VIAL, 2 mL, MULTI-DOSE VIAL Each vial contains 6 doses of 0.3 mL |
300 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, bivalent, PF, 30 mcg/0.3 mL dose | PFR | 91312 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
| 59267-1404-2 | CARTON, 10 SINGLE-DOSE VIALS | 59267-1404-1 | VIAL, 1 dose of 0.3 mL | ||||||||||
| Pfizer-BioNTech | FDA EUA updated 04/18/2023. Authorizes bivalent single-dose plus additional dose if applicable, rescinds authorization for monovalent vaccines. | Pfizer-BioNTech COVID-19 Vaccine Bivalent 5 years through 11 years(ORANGE CAP)(Tris-sucrose formulation) |
10 mcg/0.2 mL dose Original and Omicron BA.4 & BA.5 COVID-19 strains |
59267-0565-2 | CARTON, 10 MULTI-DOSE VIALS | 59267-0565-1 | VIAL, MULTI-DOSE Each vial contains 10 doses of 0.2 mL |
301 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, bivalent, PF, 10 mcg/0.2 mL dose | PFR | 91315 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use |
| Pfizer-BioNTech | FDA EUA updated 04/18/2023. Authorizes bivalent dose 1, dose 2, dose 3, rescinds authorization for monovalent vaccines.
Children who have already completed a primary series with the monovalent vaccine are eligible for an additional dose with the bivalent vaccine. |
Pfizer-BioNTech COVID-19 Vaccine Bivalent 6 months through 4 years(MAROON CAP)(Tris-sucrose formulation) |
3 mcg/0.2 mL dose Original and Omicron BA.4 & BA.5 COVID-19 strains |
59267-0609-2 | CARTON, 10 MULTI-DOSE VIALS | 59267-0609-1 | VIAL, MULTI-DOSE, 2.6 mL | 302 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose | PFR | 91317 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use |
| Novavax, Inc. | EUA Authorized | Novavax COVID-19 Vaccine | 5 mcg/0.5 mL, primary series ages 12 years and older, booster ages 18 years and older | 80631-100-10 | CARTON, 10 VIAL, MULTI-DOSE, 10 DOSES | 80631-100-01 | VIAL, MULTI-DOSE, 5 mL | 211 | SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | NVX | 91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use |
| 80631-102-10 | CARTON, 10 VIAL, MULTI-DOSE, 5 DOSES | 80631-102-01 | VIAL, MULTI-DOSE, 2.5 mL | ||||||||||
| Sanofi Pasteur | EUA Submission withdrawn. All codes will be retired | Sanofi Pasteur COVID-19 Vaccine, booster dose, adult | 5mcg/0.5mL dose, including added AS03 adjuvant, booster dose only | 49281-618-20 | 10 MULTI-DOSE VIALS, ANTIGEN ONLY | 49281-618-78 | VIAL, MULTI-DOSE, ANTIGEN | 225 | SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 5mcg/0.5mL dose | COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL | PMC | 91310 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use |
Unspecified US COVID-19 Vaccine CVX Code
| CVX Short Description | CVX Code | CVX Long Description | Note | Vaccine Status |
|---|---|---|---|---|
| SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | 213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | Unspecified code for COVID-19 not to be used to record patient US administration. May be used to record historic US administration if product is not known. CVX code 500 should be used to record Non-US vaccine where product is not known. | Inactive |
The following vaccine NDCs and associated tradenames have been either submitted for FDA authorization (Pre-Authorization) or have been authorized or approved by the FDA under EUA or BLA License and may be included in FDA NDC files and Structured Product Labels (SPL). These vaccines are listed separately because they represent NDCs that will not be manufactured or made available in the near term even if authorized.
| Manufacturer | FDA Authorization (BLA, EUA, Pre-EUA) |
Sale Proprietary Name | Product Description | Unit of Sale NDC10 (UOS) | UoS Package | Unit of Use NDC10 (UOU) | UoU Presentation | CVX Code | |
|---|---|---|---|---|---|---|---|---|---|
| Pfizer-BioNTech | BLA-licensed for ages 16+ | COMIRNATY | 30 mcg/0.3 mL for adult 16+ (original formula) | 0069-1000-02 | CARTON, 195 MULTI-DOSE VIALS | 0069-1000-01 | VIAL, 2 mL, MULTI-DOSE VIAL | NDCs not included in CDC vaccine code set | Pfizer Statement: “Pfizer received inital FDA BLA license on 8/23/2021 for its COVID-19 vaccine for use in individuals 16 and older (COMIRNATY). At that time, the FDA published a BLA package insert that included the approved new COVID-19 vaccine tradename COMIRNATY and listed 2 new NDCs (0069-1000-03, 0069-1000-02) and images of labels with the new tradename. These NDCs will not be manufactured. Only NDCs for the subsequently BLA approved tris-sucrose formulation will be produced.” |
| 00069-1000-03 | CARTON, 25 MULTI-DOSE VIALS | ||||||||
| Moderna US, Inc. | BLA-licensed for ages 18+ | SPIKEVAX | 0.5 mL dose (same as original EUA formula) | 80777-100-98 | CARTON, 10 MULTI-DOSE VIALS, EACH VIAL CONTAINING 7.5 mL | 80777-100-15 | VIAL, 7.5 mL, MULTI-DOSE VIAL | NDCs not included in CDC vaccine code set | “The following SPIKEVAX products are not anticipated to be manufactured and orderable. These NDC codes are not included in CDC Vaccine Code Set files at this time. Moderna has provided the following statement regarding the SPIKEVAX branded NDCs and labels:
“Moderna received FDA BLA license on January 31, 2022, for its COVID-19 vaccine SPIKEVAX (COVID-19 Vaccine, mRNA) for use in individuals 18 and older. At that time, the FDA published a BLA package insert that included the new approved trade name SPIKEVAX and listed 2 new NDCs for Unit of Sale cartons (80777-100-99 and 80777-100-98). The NDCs related to the Carton of 10 7.5mL vials (80777-100-98/80777-100-15) will not be manufactured. Only the SPIKEVAX NDCs 80777-100-99 and 80777-100-11 will be manufactured at this time.” |
| Moderna US, Inc. | EUA-authorized for ages 6 years to < 12 years | Moderna COVID-19 Vaccine Pediatric Vaccine (BLUE CAP) |
50 mcg/0.50 mL pediatric primary series for ages 6 yrs to <12 years | 80777-277-99 | CARTON, 10 MULTI-DOSE VIAL 2.5 mL EACH | 80777-277-05 | VIAL, 2.5 mL, MULTI-DOSE VIAL | NDCs and CVX Code 227 are currently included in CDC vaccine code set but have been inactivated. Moderna vaccines administered for 6 year to <12 year olds should utilize CVX 221 and the NDCs associated to that CVX code. | Moderna Statement: “These codes have been provided in anticipation of FDA authorization and need. At this time, even though FDA authorization may be granted under EUA, supply is not foreseen in the short term. Moderna is actively assessing demand signals to activate supply plans and working closely with USG partners to collect official demand requirements.” |
| Moderna US, Inc. | Pre-EUA Authorization | Moderna COVID-19 Vaccine Bivalent Booster | 0.5 mL dose of Original and Omicron COVID-19 strains | 80777-280-99 | CARTON, 10 MULTI-DOSE VIALS | 80777-280-05 | VIAL, 2.5 mL, MULTI-DOSE VIAL | NDCs listed here were previously published for a bivalent booster product that will not be manufactured. New formulation and NDCs are planned. CVX Code 229 will be utilized and mapped to the new NDCs for this formulation. | Moderna Statement: “NDC codes 80777-280-99 and 80777-280-05 were provided in anticipation of FDA authorization under EUA for a bivalent booster vaccine (Moderna COVID-19 Vaccine, Bivalent). A new formulation to incorporate Omicron strain BA.4/BA.5 for the booster vaccine is now being planned. The new formulation the Moderna COVID-19 Vaccine, Bivalent will be submitted to the FDA for EUA and new NDCs will be published to reflect this change. The above NDCs should be retired in systems effective 08/01/2022. At this time, there are no plans to distribute product with these NDCs.” |
Download the Preview Table for Non-US vaccine administration only: Excel Version
Preview Posting of COVID-19 Vaccine Codes and Crosswalks to be used for Non-US vaccine administration. All COVID-19 related CVX codes are associated to the Vaccine Group “COVID-19”. CVX and MVX codes are identified for vaccines that have received emergency authorization from the World Health Organization (WHO), US Food and Drug Administration (FDA) or both. CVX codes have also been added without associated MVX for vaccines that are manufactured and administered outside the US but which have not been authorized by the WHO. The list of vaccines not authorized by the WHO may be incomplete. The list of vaccines indicated to be WHO-authorized will be updated periodically as the CDC monitors WHO published information.
| CVX Code | CVX Long Description | CVX Short Description | CVX Note | CVX Status | MVX Code | MVX Manufacturer | Product Tradename(s) |
|---|---|---|---|---|---|---|---|
| 207 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg or 50 mcg dose | COVID-19, mRNA, LNP-S, PF, 100 mcg or 50 mcg dose | EUA 12/18/2020, 2-dose vaccine. Used to record Moderna vaccines administered in the US and in non-US locations (includes tradename Spikevax) | Active | MOD | Moderna US, Inc. | Moderna COVID-19 Vaccine (non-US Spikevax) |
| 208 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose | COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose | EUA 12/11/2020, 2-dose vaccine. Used to record Pfizer vaccines administered in the US and in non-US locations (includes tradename Comirnaty) | Active | PFR | Pfizer, Inc | Pfizer-BioNTech COVID-19 Vaccine (US-EUA), COMIRNATY (US-BLA), COMIRNATY (Non-US) |
| 210 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL | COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mL | WHO authorized pandemic vaccine. Recognized towards immunity in US. AstraZeneca vaccine non-US WHO authorized tradenames/identifiers include VAXZEVRIA, AZD1222, ChAdOx1 nCoV-19, COVISHIELD | Non-US | ASZ | AstraZeneca | AstraZeneca COVID-19 Vaccine (Non-US tradenames include VAXZEVRIA, COVISHIELD) |
| 211 | SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose | COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL | EUA 07/13/2022, 2-dose vaccine. Used to record Novavax vaccines administered in the US and in non-US locations (includes tradenames NUVAXOVID, COVOVAX) | Active | NVX | Novavax | Novavax COVID-19 Vaccine (Non-US Tradenames NUVAXOVID, COVOVAX) |
| 212 | SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL | COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL | EUA 02/27/2021, 1-dose vaccine. Used to record Janssen/J&J vaccines administered in the US and in non-US locations | Active | JSN | Janssen | Janssen (J&J) COVID-19 Vaccine |
| 500 | SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown | COVID-19 Non-US Vaccine, Product Unknown | Pandemic Non-US Covid Administration – specific CVX or product unknown | Non-US | |||
| 501 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN) | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 502 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN) | COVID-19 IV Non-US Vaccine (COVAXIN) | Pandemic Non-US Vaccine Authorized by WHO 11-3-2021, recognized toward immunity in US, https://extranet.who.int/pqweb/vaccines/who-recommendation-bharat-biotech-international-ltd-covid-19-vaccine-whole-virion | Non-US | BBI | Bharat Biotech International Limited | COVAXIN (Bharat) COVID-19 Vaccine |
| 503 | SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC) | COVID-19 LAV Non-US Vaccine (COVIVAC) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 504 | SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light) | COVID-19 VVnr Non-US Vaccine (Sputnik Light) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 505 | SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V) | COVID-19 VVnr Non-US Vaccine (Sputnik V) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 506 | SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology | Pandemic Non-US Vaccine. Authorized by WHO 5/19/2022 – Counted toward immunity in US | Non-US | CAN | CanSino Biologics, Inc | CONVIDECIA (CanSino Biologics) COVID-19 Vaccine |
| 507 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences) | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 508 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention) | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 509 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona) | COVID-19 PS Non-US Vaccine (EpiVacCorona) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 510 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm) | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | Pandemic Non-US Vaccine. Authorized by WHO – Counted toward immunity in US | Non-US | SPH | Sinopharm-Biotech | Sinopharm (BIBP) COVID-19 Vaccine |
| 511 | SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac) | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | Pandemic Non-US Vaccine. Authorized by WHO – Counted toward immunity in US | Non-US | SNV | Sinovac | Coronavac (Sinovac) COVID-19 Vaccine |
| 512 | SARS-COV-2 COVID-19 Virus Like Particle (VLP) Non-US Vaccine Product (Medicago, Covifenz) | SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | Pandemic Non-US Vaccine not Authorized by WHO – ACIP does recognize towards immunity in US | Non-US | MDO | Medicago, Inc | Covifenz |
| 513 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom, Zifivax) | SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 514 | SARS-COV-2 COVID-19 DNA Non-US Vaccine Product (Zydus Cadila, ZyCoV-D) | SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 515 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Medigen, MVC-COV1901) | SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 516 | SARS-COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) | COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 517 | SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Biological E Limited, Corbevax) | SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 300 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation | COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose | EUA authorized Pfizer adult bivalent booster ages 12+ yrs, original strain + omicron BA.4/BA.5. Not Authorized by WHO. Non-US Tradename for same formulation (Comirnaty Bivalent) counted toward immunity in US | Active | PFR | Pfizer, Inc | Pfizer-BioNTech COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename COMIRNATY Bivalent) |
| 229 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose | COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose | EUA authorized Moderna bivalent booster original strain + omicron BA.4/BA.5 2 dose levels: ages 6 yrs thru 11 yrs 0.25mL dose; 12 years and older 0.5mL dose. Non-US Tradename for same formulation (Spikevax Bivalent) – not authorized by WHO – is authorized by EU and counted toward US immunity | Active | MOD | Moderna US, Inc. | Moderna COVID-19 Bivalent, Original + BA.4/BA.5 (Non-US Tradename Spikevax Bivalent) |
| 518 | SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US | |||
| 519 | SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | Pandemic Non-US Vaccine not Authorized by WHO – Is authorized by EU and counted toward immunity in US | Non-US | MOD | Moderna US, Inc. | Moderna COVID-19 Bivalent, Original + BA.1 (Non-US Tradename Spikevax Bivalent) |
| 520 | SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | Pandemic Non-US Vaccine. Authorized by WHO 10/19/2022 – Counted toward immunity in US | Non-US | PFR | Pfizer, Inc | Pfizer COVID-19 Bivalent, Original + BA.1 (Non-US Tradename COMIRNATY Bivalent) |
| 521 | SARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSK | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK | Pandemic Non-US Vaccine not Authorized by WHO – not counted toward immunity in US | Non-US |
COVID-19 Emergency Use Authorization Recipient and Caregiver Fact Sheets
Preview Posting of Codes for Emergency Use Authorization (EUA) Fact Sheets for Recipients and Caregivers
Vaccine information statements (VISs), used only for licensed vaccines, will not be available for COVID-19 vaccines while they are under Emergency Use Authorization (EUA). For vaccines under an EUA, the FDA requires a vaccine-specific Fact Sheet for Recipients and Caregivers be provided to vaccine recipients or their caregivers.
The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. If a vaccine is not authorized, the code will be retired.
The FDA issued its initial Emergency Use Authorization for the Moderna COVID-19 vaccine on Friday December 18, 2020. Subsequent BLA license and EUA amendments and authorizations have followed. Information regarding the Moderna vaccines as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:
The FDA issued its initial Emergency Use Authorization for the Pfizer BioNTech COVID-19 vaccine on Friday December 11, 2020. Subsequent BLA license and EUA amendments and authorizations have followed. Information regarding the Pfizer vaccines as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:
The FDA issued its initial Emergency Use Authorization for the Janssen (Johnson & Johnson) COVID-19 vaccine on Saturday February 27, 2021. Subsequent EUA amendments and authorizations have followed. Information regarding the Janssen vaccines as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:
The FDA issued its initial Emergency Use Authorization for the Novavax COVID-19 vaccine on Wednesday July 13, 2022. Information regarding the Novavax vaccine as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link:
The following downloadable VIS code files will include the new EUA Fact Sheet for Recipients records:
| CVX Code | EUA Recipient/Caregiver Fact Sheet Description | Document Barcode String | Edition Date | Edition Status | HTML URL | PDF URL | VIS GDTI document code |
|---|---|---|---|---|---|---|---|
| 308, 310 | COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet – 6 months through 11 years | 253088698300058511230901 | 9/11/2023 | Current | https://www.cdc.gov/vaccines/covid-19/eua/pfizer-over-5-months.html | https://www.cdc.gov/vaccines/covid-19/eua/pfizer-over-5-months.pdf | 0886983000585 |
| 311 | COVID-19 Moderna EUA Recipient-Caregiver Fact Sheet – 6 months through 11 years | 253088698300061511230901 | 9/11/2023 | Current | https://www.cdc.gov/vaccines/covid-19/eua/moderna-over-5-months.html | https://www.cdc.gov/vaccines/covid-19/eua/moderna-over-5-months.pdf | 0886983000615 |
| 313 | COVID-19 Novavax EUA Recipient-Caregiver Fact Sheet – 12 years and older | 253088698300037011230901 | 10/3/2023 | Current | https://www.cdc.gov/vaccines/covid-19/eua/novavax.html | https://www.cdc.gov/vaccines/covid-19/eua/novavax.pdf | 0886983000370 |
| 309, 312 | COVID-19 Vaccine VIS – mRNA vaccine for 12 years and older | 253088698300063911231019 | 10/19/2023 | Current | https://www.cdc.gov/vaccines/hcp/vis/vis-statements/COVID-19.html | https://www.cdc.gov/vaccines/hcp/vis/vis-statements/COVID-19.pdf | 0886983000639 |
*Edition Date represents the date of update printed on the actual fact sheet document published by the FDA. It may not be the same as the EUA authorization date or the date embedded in the Document Barcode String.